Amotiv Limited (AOV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amotiv Limited (AOV) has a cash flow conversion efficiency ratio of 0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$34.09 Million ≈ $24.66 Million USD) by net assets (CA$766.79 Million ≈ $554.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amotiv Limited - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Amotiv Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AOV total liabilities for a breakdown of total debt and financial obligations.
Amotiv Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amotiv Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CJ CGV
KO:079160
|
0.158x |
|
Guangzhou Lushan New Materials Co. Ltd.
SHG:603051
|
N/A |
|
Red Violet Inc
NASDAQ:RDVT
|
0.100x |
|
Liberty Gold Corp
TO:LGD
|
-0.229x |
|
Pepper Money Ltd
AU:PPM
|
0.210x |
|
CyberPower Systems Inc
TW:3617
|
0.053x |
|
Shanghai SK Petroleum & Chemical Equipment Corp Ltd
SHE:002278
|
-0.009x |
|
Guaranty Bancshares, Inc.
NYSE:GNTY
|
0.021x |
Annual Cash Flow Conversion Efficiency for Amotiv Limited (2014–2024)
The table below shows the annual cash flow conversion efficiency of Amotiv Limited from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Amotiv Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$795.11 Million ≈ $575.17 Million |
CA$36.28 Million ≈ $26.24 Million |
0.046x | -5.18% |
| 2023-12-31 | CA$746.87 Million ≈ $540.28 Million |
CA$35.94 Million ≈ $26.00 Million |
0.048x | -1.83% |
| 2022-12-31 | CA$825.86 Million ≈ $597.41 Million |
CA$40.48 Million ≈ $29.28 Million |
0.049x | -7.50% |
| 2021-12-31 | CA$842.02 Million ≈ $609.10 Million |
CA$44.62 Million ≈ $32.28 Million |
0.053x | +484.77% |
| 2020-12-31 | CA$886.24 Million ≈ $641.09 Million |
CA$-12.21 Million ≈ $-8.83 Million |
-0.014x | -374.21% |
| 2019-12-31 | CA$915.11 Million ≈ $661.97 Million |
CA$4.60 Million ≈ $3.32 Million |
0.005x | +190.14% |
| 2018-12-31 | CA$1.03 Billion ≈ $745.11 Million |
CA$-5.74 Million ≈ $-4.15 Million |
-0.006x | -123.54% |
| 2017-12-31 | CA$991.21 Million ≈ $717.02 Million |
CA$23.46 Million ≈ $16.97 Million |
0.024x | +57.32% |
| 2016-12-31 | CA$979.72 Million ≈ $708.71 Million |
CA$14.74 Million ≈ $10.66 Million |
0.015x | +26.49% |
| 2015-12-31 | CA$642.06 Million ≈ $464.46 Million |
CA$7.64 Million ≈ $5.52 Million |
0.012x | +609.11% |
| 2014-12-31 | CA$478.99 Million ≈ $346.49 Million |
CA$803.34K ≈ $581.13K |
0.002x | -- |
About Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more